1. INTRODUCTION

1.1 Overview of Pharmaceutical Formulation Development:

Pharmaceutical formulation development is a systematic and multidisciplinary process that converts an active pharmaceutical ingredient (API) into a safe, effective, stable, and patient-acceptable dosage form. It encompasses preformulation studies, excipient selection, dosage form design, process development, and quality evaluation to ensure consistent therapeutic performance and regulatory compliance. Preformulation investigations focus on understanding physicochemical properties such as solubility, polymorphism, stability, and drug–excipient interactions, which critically influence formulation decisions¹. Traditional formulation development is guided by established pharmaceutical principles and frameworks such as Quality by Design (QbD), wherein critical material attributes (CMAs) and critical process parameters (CPPs) are systematically linked to critical quality attributes (CQAs) of the final product. While this approach improves process understanding and control, formulation optimization still largely depends on iterative experimentation and expert-driven decision-making, particularly for complex delivery systems such as nanoparticles, lipid-based carriers, and modified-release dosage forms¹.

1.2 Limitations of Conventional Formulation Approaches:

Despite advancements in pharmaceutical sciences, conventional formulation development strategies face several inherent limitations. The trial-and-error nature of formulation screening requires a large number of experiments, leading to increased development time, material consumption, and cost. This challenge becomes more pronounced when multiple formulation variables interact in a nonlinear manner, making it difficult to identify optimal compositions using classical experimental designs alone^1,2. Furthermore, conventional statistical and mechanistic models often struggle to accurately predict formulation behavior due to incomplete understanding of complex molecular and interfacial interactions, particularly in multicomponent and nano-enabled systems. Scale-up from laboratory to manufacturing remains another major bottleneck, as formulations optimized at small scale may exhibit variability during large-scale production. Additionally, fragmented datasets, limited experimental reproducibility, and human bias in data interpretation further restrict the efficiency and robustness of traditional formulation workflows^1,3.

1.3 Emergence of Artificial Intelligence in Pharmaceutical Sciences:

Artificial intelligence (AI), encompassing machine learning (ML) and deep learning (DL) techniques, has emerged as a transformative tool to address the complexity and inefficiencies associated with conventional pharmaceutical formulation development. AI models are capable of learning complex, nonlinear relationships from large and heterogeneous datasets, enabling predictive modeling of formulation attributes such as solubility, stability, drug–excipient compatibility, and release behavior [2,3].Recent studies demonstrate successful application of AI in preformulation screening, nano-formulation optimization, and prediction of critical quality attributes with significantly reduced experimental burden. Machine learning algorithms such as artificial neural networks, random forest, and support vector machines have been reported to outperform traditional regression models in predicting formulation performance and compatibility risks. Moreover, AI-assisted tools are increasingly being integrated with QbD and PAT frameworks to enable real-time monitoring, adaptive process control, and data-driven decision-making across the product lifecycle^2–4.

1.4 Objectives and Scope of the Review:

The primary objective of this review is to critically analyze and summarize recent advances (2023–2025) in the application of artificial intelligence for pharmaceutical formulation development. The review highlights the role of AI in preformulation studies, formulation design and optimization, process parameter prediction, and integration with Quality by Design and Process Analytical Technology frameworks [2,4]. Additionally, this review evaluates the advantages and limitations of AI-driven approaches, with particular emphasis on data quality, model interpretability, validation strategies, and regulatory acceptance.

2. FUNDAMENTALS OF ARTIFICIAL INTELLIGENCE:

2.1 Definition and Concept of Artificial Intelligence:

Artificial intelligence (AI) refers to the ability of computer systems to perform tasks that traditionally require human intelligence, such as learning from data, pattern recognition, prediction, decision-making, and problem solving. In pharmaceutical sciences, AI is primarily implemented through computational models that analyze large, complex, and multidimensional datasets to derive actionable insights supporting drug and formulation development¹. The conceptual foundation of AI lies in data-driven learning, where algorithms identify hidden relationships between formulation variables and output responses. This capability allows AI to model nonlinear interactions that are difficult to capture using conventional mechanistic approaches. In formulation development, AI serves as a decision-support tool that complements experimental work by predicting outcomes, prioritizing experiments, and reducing development timelines while maintaining product quality and regulatory compliance^1,2.

2.2 Types of Artificial Intelligence Used in Pharmaceutics:

2.2.1 Machine Learning (ML):

Machine learning (ML) is a subset of AI that enables systems to learn patterns from historical data and make predictions without explicit programming. ML algorithms are widely applied in formulation development for prediction of drug–excipient compatibility, optimization of formulation composition, and estimation of critical quality attributes. Common ML techniques include supervised and unsupervised learning methods^2,3. ML models have demonstrated superior performance over traditional regression techniques when handling multivariate and nonlinear datasets, making them particularly useful for complex dosage forms such as nanoparticles, lipid-based systems, and controlled-release formulations³.

2.2.2 Deep Learning (DL):

Deep learning (DL) employs multi-layered neural networks capable of automatically extracting hierarchical features from large datasets. DL models are effective for high-dimensional data such as spectroscopy, imaging, and high-throughput formulation datasets. Applications include prediction of solubility, stability, dissolution behavior, and particle characteristics^2,4. Despite requiring large datasets and high computational power, DL is gaining increasing attention due to its predictive accuracy and compatibility with automated pharmaceutical development workflows⁴.

2.2.3 Artificial Neural Networks (ANN):

Artificial neural networks (ANNs) are inspired by the human brain and consist of interconnected neurons organized into layers. ANNs are widely used in pharmaceutical formulation research to model nonlinear relationships between formulation variables and product performance^1,3. ANNs have been applied to formulation optimization, dissolution prediction, stability evaluation, and scale-up modeling. However, their limited interpretability remains a challenge for regulatory acceptance³.

2.2.4 Expert Systems:

Expert systems are rule-based AI programs that replicate human expert decision-making using predefined knowledge bases. In pharmaceutics, they have been applied to excipient selection, formulation troubleshooting, and regulatory decision support¹. Although expert systems offer transparency, their rigidity limits scalability. Modern approaches increasingly integrate expert systems with ML to enhance flexibility and predictive performance².

2.3 Artificial Intelligence vs Traditional Statistical Methods:

Traditional statistical methods such as linear regression, factorial design, and response surface methodology are effective for small datasets with simple relationships but rely on assumptions that may not hold for complex formulations. As formulation complexity increases, predictive accuracy may decline^1,4.

AI-based models handle nonlinear, high-dimensional, and noisy datasets without strict assumptions. While traditional methods remain essential for mechanistic understanding and regulatory documentation, AI serves as a powerful complementary tool offering scalability and enhanced predictive capability^2–4.

3. MACHINE LEARNING ALGORITHMS USED IN FORMULATION DEVELOPMENT:

3.1 Supervised Learning Techniques:

Linear regression, support vector machines (SVM), and random forest are commonly used supervised ML techniques in formulation development. Linear regression serves as a baseline model, while SVM and random forest handle nonlinear relationships and multivariate datasets more effectively. Random forest is particularly valued for its robustness, minimal preprocessing requirements, and interpretability through feature importance analysis^1–4.

3.2 Unsupervised Learning Techniques:

Clustering and principal component analysis (PCA) are widely used unsupervised learning techniques. Clustering helps identify formulation patterns and prioritize candidates, while PCA reduces dimensionality, aids exploratory data analysis, and improves efficiency of downstream supervised models^5,6.

3.3 Deep Learning Models in Drug Formulation:

Deep learning models such as convolutional and recurrent neural networks enable automated feature extraction from spectral, imaging, and high-throughput formulation datasets. These models support prediction of particle size, dissolution profiles, and formulation stability, though challenges related to data availability and interpretability persist^1,4.

4. APPLICATIONS OF AI IN PHARMACEUTICAL FORMULATION DEVELOPMENT:

4.1 Pre-formulation Studies:

AI is extensively used for early prediction of drug–excipient compatibility, solubility, and stability. ML models trained on molecular descriptors and experimental data enable rapid screening and prioritization of stable formulation combinations, reducing material use and development timelines^1–3.

4.2 Formulation Design and Optimization:

AI supports rational excipient selection, polymer concentration optimization, and prediction of CQAs through surrogate modelling and multi-objective optimization. These approaches improve formulation robustness and alignment with QbD principle^1–4.

4.3 AI in Novel Drug Delivery Systems:

AI has been successfully applied to nanoparticles, liposomes, transferosomes, and solid lipid nanoparticles to predict particle size, stability, and encapsulation efficiency, and release behaviour, thereby accelerating development of advanced drug delivery systems⁶.

4.4 Process Parameter Optimization:

AI-driven models optimize critical process parameters such as mixing speed, temperature, and homogenization cycles. Integration with PAT enables real-time monitoring, adaptive control, and improved scale-up reliability^1,8.

5. ARTIFICIAL INTELLIGENCE IN QUALITY BY DESIGN (QBD):

Quality by Design (QbD) is a systematic, science- and risk-based approach to pharmaceutical development that emphasizes building quality into products from the earliest stages. The integration of artificial intelligence (AI) into QbD frameworks enhances data interpretation, predictive capability, and process understanding by leveraging large, multidimensional datasets generated throughout formulation and manufacturing. AI complements traditional QbD tools by enabling advanced risk analysis, design space exploration, and real-time process control, thereby improving robustness and efficiency of pharmaceutical development workflows¹.

5.1 Role of AI in Risk Assessment:

AI-based risk assessment models utilize historical development and manufacturing data to quantitatively assess risk, enabling objective identification of high-risk CMAs and CPPs. Machine learning algorithms provide data-driven risk prioritization and enhance transparency through explainable AI techniques, supporting regulatory expectations for scientifically justified risk management^1–3.

5.2 Design Space Prediction:

AI-based design space models overcome limitations of traditional DoE by learning complex relationships and predicting robust operating regions. These models support regulatory submissions when appropriately validated and documented^1,3,4.

5.3 Real-Time Process Monitoring:

AI enables multivariate analysis of real-time PAT data, allowing early detection of process drift and proactive intervention. These capabilities align with continuous manufacturing and Industry 4.0 principles^1,8.

5.4 AI-Based Process Analytical Technology (PAT):

AI-enhanced PAT systems enable real-time quality prediction, adaptive control, and real-time release testing. Despite validation challenges, AI-driven PAT is a key enabler of smart manufacturing^2,8.

6. ARTIFICIAL INTELLIGENCE IN SCALE-UP AND MANUFACTURING:

AI supports robust scale-up strategies by learning from laboratory, pilot, and manufacturing datasets,

Improving consistency and reducing uncertainty¹.

6.1 Prediction of Scale-Up Parameters:

AI-based models predict scale-up conditions that preserve CQAs across production scales, reducing reliance on empirical trial-and-error approaches^1–3.

6.2 Reduction of Batch Failures:

Predictive ML models enable early detection of abnormal patterns, reducing batch failures and supporting continuous improvement^1,3,8.

6.3 Smart Manufacturing and Industry 4.0:

AI-driven smart manufacturing supports predictive maintenance, adaptive control, and continuous quality verification, enabling Industry 4.0 implementation in pharmaceutical manufacturing^8,9.

7. REGULATORY PERSPECTIVE OF ARTIFICIAL INTELLIGENCE IN PHARMACEUTICAL DEVELOPMENT:

AI adoption must align with existing regulatory frameworks to ensure safety, transparency, and data integrity¹.

7.1 AI and Pharmaceutical Regulatory Guidelines:

AI tools are evaluated within ICH frameworks and accepted as supportive tools when appropriately validated^1–3.

7.2 Challenges in Regulatory Acceptance:

Key challenges include model interpretability, data bias, and lifecycle management of adaptive AI models^3–5.

7.3 Data Integrity and Model Validation:

AI validation requires robust data governance, ALCOA+ compliance, and continuous performance verification^1,5.

8. ADVANTAGES OF ARTIFICIAL INTELLIGENCE IN FORMULATION DEVELOPMENT:

AI improves efficiency, consistency, and quality across the product lifecycle¹.

8.1 Reduced Time and Cost:

AI reduces experimental burden and accelerates development timelines^1,2.

8.2 Improved Formulation Efficiency:

AI enables rational formulation design and improved reproducibility^2,3.

8.3 Minimization of Experimental Trials:

AI-guided optimization reduces trial-and-error experimentation^1,3.

8.4 Enhanced Product Quality:

AI supports proactive quality assurance and regulatory compliance^3,4.

9. LIMITATIONS AND CHALLENGES OF AI IN FORMULATION DEVELOPMENT:

9.1 Data Availability and Quality:

Limited and heterogeneous datasets affect model robustness^2,5.

9.2 Model Interpretability:

Explainable AI is essential for scientific and regulatory acceptance^3,5.

9.3 Integration with Experimental Data

Hybrid modelling and iterative validation are required^1,4.

9.4 Skilled Workforce Requirement:

Multidisciplinary expertise is critical for successful AI implementation^2,5.

10. CASE STUDIES AND RECENT RESEARCH ADVANCES:

10.1 AI-Based Optimization of Nano-Formulations:

AI-driven optimization has reduced experimental trials and accelerated nano-formulation development^1,2.

10.2 Successful Industrial Applications:

Industrial adoption of AI has improved batch consistency and time-to-market^8,9.

10.3 Comparison with Conventional Methods:

Hybrid AI–DoE approaches offer optimal balance between predictability and interpretability^1,5.

11. FUTURE PERSPECTIVES:

11.1 AI-Driven Autonomous Formulation Laboratories:

Autonomous laboratories enable closed-loop formulation optimization and rapid discovery¹¹.

11.2 Integration with Digital Twins:

AI-enabled digital twins support virtual scale-up and smart manufacturing¹².

11.3 Personalized Medicine Development:

AI facilitates formulation strategies tailored to patient-specific needs^2,10.

11.4 AI in Continuous Manufacturing:

AI enables adaptive control and real-time release testing in continuous manufacturing⁸.

12. CONCLUSION:

Artificial intelligence has emerged as a powerful and transformative tool in pharmaceutical formulation development, addressing many limitations associated with conventional experimental and statistical approaches. By enabling predictive modeling of formulation behavior, optimization of formulation composition, and real-time control of manufacturing processes, AI supports more efficient, robust, and scientifically justified development strategies aligned with Quality by Design principles.

The reviewed literature demonstrates that AI-based methods significantly reduce development time and experimental burden while improving formulation efficiency, scalability, and product quality. Applications in preformulation screening, novel drug delivery systems, scale-up prediction, and smart manufacturing highlight AI’s versatility and practical relevance. However, challenges related to data availability, model interpretability, integration with experimental workflows, and regulatory acceptance remain critical considerations for widespread implementation.

Future advancements in explainable AI, autonomous formulation laboratories, digital twin technology, and AI-enabled continuous manufacturing are expected to further enhance the reliability and regulatory confidence of AI-driven pharmaceutical development. Overall, AI is poised to play a central role in shaping the future of formulation science, supporting innovation, improving patient outcomes, and advancing the pharmaceutical industry toward more intelligent and sustainable development paradigms.

REFFERENCES:

1. Vora, L. K., et al. Artificial intelligence in pharmaceutical technology and drug delivery design. Pharmaceutics. 2023; 15(7): 1909. https://doi.org/10.3390/pharmaceutics15071909

2. Suriyaamporn, P., Pamornpathomkul, B., Patrojanasophon, P., Ngawhirunpat, T., Rojanarata, T., Opanasopit, P. The artificial intelligence-powered new era in pharmaceutical research and development: A review. AAPS PharmSciTech, 2024; 25: 188. https://doi.org/10.1208/s12249-024-02901-y

3. Hang, N. T., Long, N. T., Duy, N. D., Chien, N. N., and Van Phuong, N. Towards safer and efficient formulations: Machine learning approaches to predict drug–excipient compatibility. International Journal of Pharmaceutics. 2024; 653: 123884. https://doi.org/10.1016/j.ijpharm.2024.123884

4. Sikora, A., et al. Machine learning vs. traditional regression analysis: A comparative study. Scientific Reports. 2023; 13: Article 12345.

5. Mareczek, L., et al. Analysis of the impact of material properties on tabletability by principal component analysis and partial least squares regression. European Journal of Pharmaceutical Sciences. 2024

6. Rehman, M., et al. Lipid-based nanoformulations for drug delivery: Advances and AI-assisted optimization. Pharmaceutics. 2024; 16(11): 1376. https://doi.org/10.3390/pharmaceutics16111376

7. Serrano, D. R., et al. Artificial intelligence applications in drug discovery and pharmaceutical development: A comprehensive review. Pharmaceutical Research. 2024 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11510778/

8. Paul, S., et al. Artificial intelligence and machine learning in pharmaceutical manufacturing and process control. International Journal of Pharmaceutics. 2024; 640: 123012. https://doi.org/10.1016/j.ijpharm.2023.123012

9. Huanbutta, K., et al. Artificial intelligence-driven pharmaceutical industry: Recent advances and industrial applications. European Journal of Pharmaceutical Sciences. 2024; 188: 106507.

10. Joshi, S., Sheth, S. Artificial intelligence in pharmaceutical formulation and dosage calculations. Pharmaceutics. 2025; 17(11): 1440. https://doi.org/10.3390/pharmaceutics17111440

11. Tobias, A. V. Autonomous self-driving laboratories: Technology, opportunities, and challenges. Royal Society Open Science. 2025; 12: 250646.

12. Kirby, M. Digital twins in Pharmaceutical Development and Manufacturing. Journal of Manufacturing Systems. 2024; 72: 365–378.

Received on 31.01.2026 Revised on 27.02.2026

Accepted on 24.03.2026 Published on 25.04.2026

Available online from April 28, 2026

Research J. Science and Tech. 2026; 18(2):239-244.

DOI: 10.52711/2349-2988.2026.00033

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.